Comparative central nervous system effects and pharmacokinetics of neu- metoclopramide and metoclopramide in healthy volunteers

Journal of Clinical Pharmacology

Volumn 37, Issue 3, 1997, Pages 222-228

  Rotmensch, Heschi H ^a   Mould, Graham P ^b   Sutton, J Andrew ^b   Kilminster, Shaun ^b   Moller, Claus ^c   Pero, Ronald W ^c,d  

^a CATO RESEARCH LTD   (United States)

^b Surrey County Hospital   (United Kingdom)

^c Oxigene Inc   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

METOCLOPRAMIDE; NEU METOCLOPRAMIDE; PLACEBO; SODIUM CHLORIDE; SODIUM METABISULFITE; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG CONFORMATION; DRUG EFFECT; DRUG FORMULATION; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HUMAN; HUMAN EXPERIMENT; INSOMNIA; INTRAMUSCULAR DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; IRRITABILITY; LETHARGY; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; VOMITING;

EID: 0030896798     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1552-4604.1997.tb04784.x     Document Type: Article

References (20)

1. Harrington RA, Hamilton CW, Brogden RN, Linkewich JA, Romankiewicz JA, Heel RC: Metoclopramide, an updated review of its pharmacological properties and clinical use. Drugs 1983;25: 451-494.
2. Pinder RM, Brogden RN, Sawyer PR, Speight TM, Avery GS: Metoclopramide, a review of its pharmacological properties and clinical use. Drugs 1976;12:81-131.
3. Lybak S, Kjellen E, Wennerberg J, Pero RW: Metoclopramide enhances the effect of ionizing radiation on xenografted squamous cell carcinoma of the head and neck. Int J Radial Biol Phys 1990;19:1419-1424.
4. Hua J, Olsson A, Sheng Y, Pero RW: Acidic and neutralized metoclopramide formulations sensitize ionizing radiation induced cytoxicity in a human lung adenovarcinoma xenografted to scid mice. Anticancer Drugs 1995;6:451-455.
5. Kjellen E, Wennerberg J, Pero RW: Metoclopramide enhances the effect of cisplatin on xenografted squamous cell carcinoma of the head and neck. Br J Cancer 1989;59:247-250.
6. Werning JW, Stepnick DW, Jafri A, Megeian CA, Antunez AR, Zaidi SIA: Metoclopramide enhances the effect of photodynamic therapy on xenografted squamous cell carcinoma of the head and neck. Acta Otolaryngol Head Neck Surg 1995;121:783-789.
7. Lybak S, Wennerberg J, Kjellen E, Pero RW: Dose schedule evaluation of metoclopramide as a potentiator of cisplatin and carboplatin treatments of xenografted squamous cell carcinomas of the head and neck. Anticancer Drugs 1991;2:375-382.
8. Salford LG, Pero RW, Ass AT, Brun A: Metoclopramide as a sensitizer of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU) treatment of brain tumors in the rat. Anticancer Drugs 1992;3:267-272.
9. Kjellan E, Pero RW, Brun E, Ewers S-B, Jarlman O, Knös T, et al: A Phase I/II evaluation of metoclopramide as a radiosensitizer in patients with inoperable squamous cell carcinoma of the lung. Eur J Cancer 1995;31(suppl A):2196-2202.
10. Lybak S, Pero RW: The benzamide derivative metoclopramide causes DNA damage and inhibition of DNA repair in human mononuclear leucocytes at clinically relevant doses. Carcinogenesis 1991;12:1613-1617.
11. Olsson A, Sheng Y, Kjellan E, Pero RW: In vivo tumor measurements of DNA damage, DNA repair and NAD pools as indicators of radiosensitisation by metoclopramide. Carcinogenesis 1995;16:1029-1035.
12. Pero RW, Anderson MW, Doyle GR, Anna CH, Romogna F, Markowitz MM, Bryngelsson C: Oxidative stress induces DNA damage and inhibits the repair of DNA lesions induced by N-Acetoxy-2-acetylamino fluoene in human peripheral mononuclear leucocytes. Cancer Res 1990;50:4619-4625.
13. Pero RW, Steng Y, Olsson A, Bryngelsson C, Lund-Pero M: Hypochlorous acid/N-chloramines are naturally produced DNA repair inhibitors. Carcinogenesis 1996;17:13-17.
14. Pero RW, Simanaitis M, Olsson A, Amiri A, Andersen I: Pharmacokinetics, toxicity, side effects, receptor affinities and in vitro radiosensitizing effects of the novel metoclopramide formulations Sensamide and Neu-Sensamide. Pharmacol Toxicol. Submitted, 1996.
15. Kilminster SK, Sutton JA, Mould GP: Anxiety model in healthy volunteers (abstract). Br J Clin Pharmacol 1995;39:543P.
16. Starkey BS, Mould GP: Assay of metoclopramide in serum by high performance liquid chromatography. Proceedings of Association of Clinical Biochemistry National Meeting, May 15-19, 1995;168.
17. Spielberger CD: STAI Manual. Palo Alto, CA: Consulting Psychologists Press, 1970.
18. Topart J, Hanocq M, van Damme M, Molle L: Spectroscopic study of several N-(Diethylamine-2-ethyl) substituted benzamides. J Pharm Belg 1973;28:633-648.
19. Hanoq M, Topart J, van Damme M, Molle L: Determination des constantes d'ionisation de quelques N-(diethylamino-2ethyl) benzamides substitues. J Pharm Belg 1973;28:649-662.
20. Bryson SM, McGovern EM, Kelman AW, Whie K, Addis GJ, Whiting B: The pharmacokinetics of high-dose metoclopramide in patients with neoplastic disease. Br J Clin Pharmacol 1985;19: 757-766.